Rare Diseases Clinical Trial
— CHICOfficial title:
Efficacy of Intact Cord Resuscitation Compared to Immediate Cord Clamping on Cardiorespiratory Adaptation at Birth in Infants With Isolated Congenital Diaphragmatic Hernia (CDH)
Isolated CDH is a rare disease (1/3500) and displays a wide range of severity and outcome. Despite attempts to standardize the management of this disease at birth and during the first months of life, the mortality varies from 20 to 50% according to different hospitals in France and abroad. Several studies already showed the benefice of late cord clamping at birth on biological and physiological adaptation of newborns to life. Previous works also suggest a possible benefit of this procedure for babies with CDH. This multicenter randomized clinical study aims to investigate the efficacy of intact cord resuscitation compared to immediate cord clamping on cardiorespiratory adaptation at birth in full term newborn infants with isolated CDH.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | October 2025 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 36 Weeks to 37 Weeks |
Eligibility | Inclusion Criteria: - Antenatal diagnosis of CDH - No severe additional malformation or chromosomal diseases - Full term (>36 weeks gestational age) - No inclusion in another antenatal trial - Written informed consents from the parents Exclusion Criteria: - Preterm birth less than 37 weeks gestational age - Other severe malformation(s) or chromosomal diseases - Twin - Parents who may have French language understanding difficulties may not participate to the study unless they receive appropriate assistance regarding the understanding of the formal consent forms needed to get included in the study. If included in the study, regarding their French understanding level, the parents may not be proposed the auto questionnaires and interviews led by the psychologist |
Country | Name | City | State |
---|---|---|---|
France | Chu Amiens Picardie | Amiens | |
France | Hop Jeanne de Flandre Chu Lille | Lille | |
France | Chu de Nantes - | Nantes |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | Ministry of Health, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of infants with APGAR score < 4 at 1 min or < 7 at 5 min. | during the first ten minutes after birth | ||
Primary | APGAR score | APGAR at 1, 5 and 10 minutes after birth will be reassessed retrospectively by a final observer. The reassessment will be carried out using a video of the first 10 minutes of life of the newborn filmed with a camera if the parents agree. This video will only record the appearance of babies' bodies and faces | during the first ten minutes after birth | |
Secondary | Frequency of postpartum hemorrhage (PPH) defined by blood loss = 500 ml | during the deliverance time | ||
Secondary | Frequency of severe PPH, defined by measured blood loss = 1000 ml | during the deliverance time | ||
Secondary | Blood loss volume after birth | the collector bag will have to be left in place at least 15 minutes to have one measure of blood loss at the same time point in all women | at 15 minutes after birth, at 1hours after birth | |
Secondary | Frequency of infants with the need for chest compressions | during the deliverance time | ||
Secondary | Frequency of infants with the need for epinephrine administration and/or fluid resuscitation | during the deliverance time | ||
Secondary | Heart rate | a pulse oximeter sensor will be placed at the right hand as soon as possible (within the first minute after birth), which then will be connected to a pulse oximeter; | at 1, 5, and 10 min after birth and at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days | |
Secondary | plasma lactate concentration | these quantitative variables can be considered as objective markers of early cardiorespiratory adaptation at birth. | at one hour after birth (H1): at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days | |
Secondary | changes of global Blood gases parameters | pre- and postductal SpO2, | at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days | |
Secondary | changes of ventilatory parameters | peak inspiratory pressure | at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days | |
Secondary | changes of ventilatory parameters | respiratory rate | at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days | |
Secondary | Volume of fluid resuscitation | during the first 24 hours | ||
Secondary | Frequency of infants with the need for vasoactive drugs ; | during the first 24 hours | ||
Secondary | Frequency of infants with the need for pulmonary vasodilator | during the first 24 hours | ||
Secondary | Hemoglobin concentration | at 24 hours | ||
Secondary | Infant mortality rate | at 90-day after birth | ||
Secondary | Infant morbidity outcomes assessed within the first 90 days after birth | at 90-day after birth | ||
Secondary | Number of refusal of participating to the protocol. | the reasons for refusal will be recorded : do not want to participate to a research protocol, to not want to be randomized in the immediate cord clamping group, to not want to be randomized in the intact cord resuscitation group; | at the end of the study period (90±7 days after birth) | |
Secondary | State Trait Anxiety Inventory (STAI) revised version, form Y | The STAI is a self-report scale translated in French (1). The scale includes 20 questions, and takes approximately 5 minutes to complete. It is widely used and usually well accepted. Both parents will be requested to answer the questionnaire at two distinct moments. The first will be within the first 48 hours after birth, and the second will be during the medical consultation at the end of the study period (90±7 days after birth). | within the first 48 hours after birth, and at the end of the study period (90±7 days after birth). | |
Secondary | the Impact of Event Scale-Revised (IES-R) | The IES-R is made up of 22 items aimed at assessing three main factors of traumatic symptoms (intrusion, avoidance and numbing, and hyperarousal) linked to a specific stressful event. The questions pertain to symptoms occurring during the 7 days prior to completion. The scale usually takes approximately 5 minutes to complete. Parents will be requested to answer the questionnaire during the medical consultation at the end of the study period (90±7 days after birth). | during the 7 days prior to completion and at the end of the study period (90±7 days after birth). | |
Secondary | the Intolerance for Uncertainty Scale (EII). | This self-report scale was originally designed in French and includes 27 questions pertaining to the beliefs and representations held by individuals with regards to uncertainty. The scale is usually completed in approximately 10 minutes. Parents will be requested to answer the questionnaire during the medical consultation at the end of the study period (90±7 days after birth). | at the end of the study period (90±7 days after birth). | |
Secondary | Semi-structured interviews | Semi-structured interviews will be proposed by a psychologist to the parents whatever the issue, to assess their personal experience of the resuscitating period at birth, including both early/delayed cord clamping and close/remote resuscitation maneuvers. The interviews tape recordings will be transcribed and then analyzed using thematic coding. The anonymized data will be independently coded by three researchers and compared for consistency of interpretation. The themes that emerged following the final coding will be used for a qualitative analysis of the parental verbatim; Due to he's or her's initial condition (HCD), if the newborn dies before the end of the study, the parents will not be asked to get through the psychological questionnaires and interviews | at the end of the study period (12 months after birth) | |
Secondary | the 'faceless' acute neonatal pain scale (FANS) | FANS, which doesn't include items on facial expression, is particularly adapted for evaluating acute pain in newborns during intubation. Pain assessment is based on the analysis of limb movement, vocal expression and autonomic reactions, including heart rate variations and the occurrence of bradycardia or desaturation. | during intubation | |
Secondary | Cerebral Near-infrared spectroscopy recorded | at H1, H2, H6, H12, H24, H48 | ||
Secondary | Echographic parameters with the Resistive index and pulsatility index in the anterior cerebral artery | at H6, H24, H24 after the chirurgical CDH repair gesture, H48, D7, D28 | ||
Secondary | A parental questionnaire to assess neurological development (ASQ 3 score). | at M6 and M12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05794217 -
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
|
||
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Completed |
NCT03290469 -
NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants
|
N/A | |
Not yet recruiting |
NCT05955794 -
Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes
|
N/A | |
Not yet recruiting |
NCT04152876 -
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
|
||
Recruiting |
NCT03683966 -
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
|
||
Not yet recruiting |
NCT04319796 -
European Registry on Rare Neurological Diseases
|
||
Completed |
NCT02736565 -
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT05070988 -
Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
|
||
Completed |
NCT03563677 -
Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases
|
N/A | |
Recruiting |
NCT05499091 -
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
|
N/A | |
Completed |
NCT03954652 -
Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"
|
N/A | |
Recruiting |
NCT05703893 -
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
|
||
Enrolling by invitation |
NCT04703179 -
Rare and Undiagnosed Disease Research Biorepository
|
||
Recruiting |
NCT04024774 -
Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
|
||
Recruiting |
NCT06343558 -
Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
|
||
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Enrolling by invitation |
NCT04654000 -
Rheopheresis as Adjuvant Treatment of Calciphylaxis
|
N/A | |
Recruiting |
NCT04651439 -
Severe Bullous Drug Eruption and Filgrastim
|
Phase 2/Phase 3 | |
Recruiting |
NCT03491280 -
Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases
|